Humira is a biologic therapy primarily used to treat autoimmune diseases, many patients requires high dose of the drug on long term basis. Biosimilars provides affordable treatment alternative to reference biologics due to their reduced development and manufacturing costs. As patent exclusivity of Humira is expiring in major markets by 2023, several pharmaceutical companies are investing in developing Humira biosimilars.
The global Humira Biosimilar Market is ... Read more
